Prior to joining Boundless Bio, Scott was at Genentech where he served in roles of increasing responsibility across business development, development, and commercial organizations. Most recently he was the Director of Oncology Business Development for Roche/Genentech, focusing on targeted therapies for driver mutations and tumor agnostic approaches to oncology. In that role, he was actively involved in several deals at Roche/Genentech, including leading the acquisition of Ignyta for $1.7 billion in February 2018. During his time at Genentech, he was team lead of an early development oncology program and played a key role in launching Tarceva (erlotinib) in 1L EGFRm+ NSCLC. Scott holds a B.S. in biology and chemistry from the University of North Carolina, Chapel Hill. After completing his doctorate in molecular oncology and genomic sciences from North Carolina State University, he joined the neurosurgery departments at the University of California San Francisco as a postdoctoral researcher.